Introduction
============

Pancreatic cancer (PC) remains a lethal disease, with an overall 5-year survival rate of \~5%.[@b1-ott-11-903],[@b2-ott-11-903] Even after radical pancreatectomy, there is a high probability of systemic and/or local recurrence, and the median survival is onlŷ1 year, suggesting that surgery alone is generally inadequate.[@b3-ott-11-903],[@b4-ott-11-903]

Hepatic metastasis is a common cause of treatment failure after curative resection of PC.[@b5-ott-11-903] Accordingly, chemotherapy represents one of the most important postresection therapeutic strategies in the treatment of PC. However, currently, the commonly used chemotherapy still cannot achieve a satisfactory clinical curative effect and has serious adverse reactions. Consequently, it is of great value to develop alternative treatment regimens. Our previous study revealed that hepatic arterial infusion chemotherapy (HAIC) significantly prevented metachronous hepatic metastases from colorectal cancer and improved the prognosis.[@b6-ott-11-903] Therefore, this retrospective study aimed to determine whether HAIC has the potential to prevent hepatic metastasis and improve the prognosis of patients with PC after radical pancreatectomy.

Methods
=======

Patients
--------

During June 2008 and May 2013, 87 patients with PC underwent radical pancreatectomy in the First People's Hospital affiliated to Huzhou Normal College. Among these patients, after surgery, 43 received two sessions of HAIC followed by four sessions of systemic chemotherapy (HAIC group), while 44 received six sessions of systemic chemotherapy alone (control group). The main inclusion criteria were as follows: histologically confirmed as ductal adenocarcinoma of the pancreas, no prior cancer therapy, Karnofsky performance score (KPS) ≥70, postresection survival time \>6 months, Child--Pugh Classes A--B, adequate bone marrow and renal function, and aged from 18 to 75 years. The medical records of these patients were retrospectively reviewed. The baseline characteristics, complications, toxicities, and long-term survival were collected and compared. Patients chose treatment modality by themselves after being told by the doctors about advantages and disadvantages of each treatment modality. After choosing the treatment modality, all patients signed a written informed consent form for the treatment. This research was approved by the ethics committee of the First People's Hospital affiliated to Huzhou Normal College.

Chemotherapy administration
---------------------------

Chemotherapy was begun within 28 days postsurgery and administered every 4 weeks. Both the HAIC and systemic chemotherapy regimen included 5-fluorouracil and gemcitabine.[@b7-ott-11-903] In this study, 5-fluorouracil (1,000 mg/m^2^) was administered as a 5-h infusion on day 1 and gemcitabine (800 mg/m^2^) was administered as an over 30-min infusion on days 1 and 8.

In the HAIC group, chemotherapy agents were infused through a catheter, with one end inserted into the common hepatic artery or proper hepatic artery, and the other end linked to the infusion pump.[@b8-ott-11-903] After infusion, the infusion catheter was withdrawn. Toxicities and complications were observed and managed by symptomatic therapies. Chemotherapy would be discontinued once life-threatening toxicities or complications occurred or according to the patients' request. The National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0,[@b17-ott-11-903] was used to evaluate toxicities.

Follow-up
---------

All patients had a follow-up visit every month during the first year after surgery and every 3 months thereafter. The follow-up visit included physical examination, biochemical tests, measurement of tumor markers, and thoracic and abdominal imaging examination. Relapse or metastasis was detected by imaging and, if necessary, biopsy. Repeat chemotherapy with the same regime was administered as soon as relapse or metastasis was diagnosed. Alternative regimens consisting of combinations of gemcitabine, oxaliplatin, or capecitabine were administered if the disease was not controlled.

Statistical analysis
--------------------

All measurements were expressed as mean ± SD. Student's *t*-, chi-square, or Fisher's exact test was appropriately applied to analyze the clinical data. Survival curves were obtained using the Kaplan--Meier method and compared using the log-rank test. For all tests, *P*\<0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

There was no significant difference between the two groups in patient characteristics, such as gender, age, operating time, tumor stage, tumor location, lymph nodal involvement, portal vein invasion, blood loss during surgery, tumor differentiation, tumor size, or serum carbohydrate antigen 19-9 (CA19-9) level ([Table 1](#t1-ott-11-903){ref-type="table"}).

Disease-free survival
---------------------

During the first 5 postresection years, 35 patients from the HAIC group and 38 patients from the control group developed relapse or metastasis. Details of recurrent sites are shown in [Table 2](#t2-ott-11-903){ref-type="table"}. No significant difference was found in the 5-year disease-free survival probability between the two groups (*P*=0.2029, hazard ratio for recurrence=0.7561; 95% CI=0.4768--1.1989, by the log-rank test) ([Figure 1](#f1-ott-11-903){ref-type="fig"}).

Overall survival
----------------

During the first 5 postresection years, 32 patients from the HAIC group and 36 patients from the control group died. The HAIC group had a significantly higher 5-year overall survival probability than the control group (*P*=0.0288, hazard ratio for death=0.6059; 95% CI=0.3734--0.9832, by the log-rank test) ([Figure 2](#f2-ott-11-903){ref-type="fig"}).

Hepatic metastases-free survival
--------------------------------

During the first 5 postresection years, hepatic metastases were reported in 15 patients from the HAIC group and 20 patients from the control group. Survival analysis ([Figure 3](#f3-ott-11-903){ref-type="fig"}) showed a significantly higher 5-year hepatic metastases-free survival probability in the HAIC group compared with the control group (*P*=0.0321, hazard ratio for hepatic metastases=0.5006; 95% CI=0.2546--0.9843, by the log-rank test).

Toxicity and complication
-------------------------

Chemotherapy-related toxicities are shown in [Table 3](#t3-ott-11-903){ref-type="table"}, and no significant difference was observed between the two groups. No chemotherapy-related deaths were recorded. No life-threatening toxicity or complication was reported. All patients completed six sessions of chemotherapy. All side effects and complications were ameliorated by symptomatic therapies. Hematoma of the femoral artery puncture site was reported in three patients after the HAIC procedure and was controlled by pressure bandage.

Discussion
==========

In order to improve the long-term survival of patients with PC, surgeons usually conduct radical pancreatectomy, including extensive lymph node dissection and complete resection of the extra pancreatic nerve plexus of the superior mesenteric artery or celiac axis.[@b9-ott-11-903],[@b10-ott-11-903] However, postresection recurrence rate remains high, even in patients who received margin-negative (R0) resections. Hepatic metastasis is one of the major causes of treatment failure after radical pancreatectomy. HAIC is a well-established therapeutic and prophylactic option for hepatic metastases from colorectal cancer.[@b6-ott-11-903] Some studies have shown that HAIC has beneficial effects on unresectable PC and postresection hepatic metastases, and can assist in the prevention of postresection hepatic cancer recurrence.[@b11-ott-11-903],[@b12-ott-11-903] Accordingly, HAIC might be an attractive treatment option, because infusion of chemotherapy agents through the hepatic arterial circulation can achieve high local concentrations with minimal systemic side effects.[@b13-ott-11-903]--[@b15-ott-11-903]

It was demonstrated that gemcitabine combined with fluorouracil drugs significantly improved overall survival and increased 1-year survival probability and objective response rate compared to gemcitabine alone in patients with PC.[@b16-ott-11-903] Therefore, gemcitabine combined with fluorouracil drugs may be considered as an acceptable alternative treatment for PCs. Both the HAIC and systemic chemotherapy regimen in our study included 5-fluorouracil and gemcitabine.

In our study, patients in the HAIC group had significantly higher overall survival and hepatic metastases-free survival than the control group. However, the disease-free survival showed no difference between the two groups, suggesting that the survival benefit of HAIC could be attributable to the decreased hepatic recurrence.

Our study also confirmed the safety of the HAIC procedure. The toxicity and complication of the HAIC group were similar to the control group. None of the symptoms was severe, and all were controlled by the conservative therapies in both groups.

Conclusion
==========

HAIC has the potential to prevent hepatic metastases and increase the long-term survival probability of patients with PC after radical pancreatectomy. Due to the retrospective nature and the small sample number of the present study, a further prospective study with a larger sample number is needed to confirm the results of our study.
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###### 

Patient characteristics

  Characteristics                  Control (n=44)   HAIC (n=43)   *P*-value
  -------------------------------- ---------------- ------------- -----------
  Age (years)                      57.2±6.4         58.8±5.9      0.2290
  Serum CA19-9 (U/mL)              687.9±88.9       712.4±94.1    0.2152
  Tumor size (cm)                  3.8±1.4          4.2±1.9       0.2660
  Operating time (min)             157.2±51.2       162.4±55.7    0.6513
  Blood loss during surgery (mL)   375.2±67.8       386.8±75.3    0.4521
  Gender                                                          0.7604
   Male                            32               30            
   Female                          12               13            
  Tumor stage                                                     0.8439
   I                               3                2             
   II                              22               24            
   III                             19               17            
  Portal vein invasion                                            0.8909
   Positive                        17               16            
   Negative                        27               27            
  Tumor differentiation                                           0.9852
   Well                            6                7             
   Moderately                      11               10            
   Poorly                          24               22            
   Adenosquamous                   3                4             
  Lymph nodal involvement                                         0.6763
   Positive                        40               41            
   Negative                        4                2             
  Tumor location                                                  0.6867
   Head                            27               28            
   Body                            9                10            
   Tail                            8                5             

**Note:** Data are presented as mean ± SD.

**Abbreviations:** HAIC, hepatic arterial infusion chemotherapy; CA19-9, carbohydrate antigen 19-9.

###### 

Sites of recurrence

  Recurrence event            Local   Lung   Brain   Bone   Liver
  --------------------------- ------- ------ ------- ------ -------
  Sites of first recurrence                                 
   HAIC group                 12      5      3       6      9
   Control group              14      4      4       4      12
  Sites of any recurrence                                   
   HAIC group                 13      8      7       8      15
   Control group              16      7      7       6      20

**Abbreviation:** HAIC, hepatic arterial infusion chemotherapy.

###### 

Toxicities

  Adverse event      Control group   HAIC group   *P*-value                          
  ------------------ --------------- ------------ ----------- --- ---- ---- ---- --- --------
  Neutropenia        21              16           7           0   19   15   9    0   0.6258
  Thrombocytopenia   18              8            8           0   20   7    6    0   0.6408
  Anemia             22              9            10          0   19   11   9    0   0.9891
  Nausea/vomiting    17              17           10          0   20   12   11   0   0.7094
  Diarrhea           9               7            3           0   5    6    4    0   0.6038
  Nephrotoxicity     10              7            5           0   8    6    3    0   0.3178
  Hepatic toxicity   7               4            3           0   10   6    4    0   0.1803
  Stomatitis         11              7            4           0   9    6    4    0   0.6592
  Allergy            12              4            2           0   13   5    1    0   0.8107

**Abbreviation:** HAIC, hepatic arterial infusion chemotherapy.
